IMAB - I-Mab

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
24.93
+0.58 (+2.38%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close24.35
Open24.93
Bid24.40 x 1100
Ask25.90 x 800
Day's Range24.03 - 25.18
52 Week Range9.30 - 32.89
Volume15,812
Avg. Volume61,129
Market Cap1.442B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMar 31, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.34
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • The Daily Biotech Pulse: PhaseBio To Start Potential Pivotal COVID-19 Trial, Immunomedics CEO Quits, Tetraphase Receives Sweetened Offer
      Benzinga

      The Daily Biotech Pulse: PhaseBio To Start Potential Pivotal COVID-19 Trial, Immunomedics CEO Quits, Tetraphase Receives Sweetened Offer

      Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 27) * ADC Therapeutics SA (NYSE: ADCT) (went public May 15) * Aeglea Bio Therapeutics Inc (NASDAQ: AGLE) * argenx SE - ADR (NASDAQ: ARGX) * ChemoCentryx Inc (NASDAQ: CCXI) * Imara Inc NASDAQ: (IMRA) * Immunovant Inc (NASDAQ: IMVT) * Mersana Therapeutics Inc (NASDAQ: MRSN) (announced positive interim Phase 1 data for XMT-1536 in patients with ovarian cancer) * Vermillion, Inc. (NASDAQ: VRML)Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 27) * Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) (announced publication of positive data for its antibiotic in treating bacteremia and endocarditis) * Sonnet Biotherapeutics Holdings Inc (NASDAQ: SONN) * Teligent Inc (NEW JERSEY) (NASDAQ: TLGT)Stocks In Focus PhaseBio Gets FDA Nod For Potentially Pivotal Trial Of COVID-19 Treatment PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) announced FDA authorization to proceed with VANGARD, a potentially pivotal clinical trial to evaluate PB1046 as a treatment for hospitalized COVID-19 patients who are at high risk for rapid clinical deterioration and acute respiratory distress syndrome.PhaseBio said it expects to begin dosing patients by the end of June and report trial results late in the fourth quarter of 2020.The stock was jumping 54.3% to $6.82 in Thursday's premarket session.Roche To Commence Late-Stage Study Of COVID-19 Combo Treatment Option With Gilead's Remdesivir Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY) announced the initiation of a global Phase 3 study to evaluate the safety and efficacy of Actemra/RoActemra plus the investigational antiviral remdesivir versus placebo plus remdesivir in hospitalized patients with severe COVID-19 pneumonia, in collaboration with Gilead Sciences, Inc. (NASDAQ: GILD).Roche aid it expects to enroll patients in the study in June, with the results likely to be available in the summer.Separately, Roche announced European approval of a new, shorter 2-hour Ocrevus infusion time, dosed twice yearly, for relapsing or primary progressive multiple sclerosis.Tetraphase Receives Sweetened Offer From Melinta After AcelRx's Revised Offer Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) said its board has received a revised proposal from Melinta amending its prior acquisition proposal. In light of the amended offer, Tetrephase said the Melinta offer is a superior offer.Tetraphase said it has notified AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) of the amended Melinta proposal, the superior offer determination and its intention to consider changing its recommendation or terminating the AcelRx offer unless AcelRx proposes revisions to the terms on or prior to Monday, June 1.This follows AccelRx sweetening its earlier offer to $30 million in stock and cash based on the AcelRx closing share price on May 22, plus an additional $14.5 million in contingent value rights payable in cash. See also: The Week Ahead In Biotech: ASCO Presentations In The Spotlight Aerpio To Collaborate With Quantum Leap In COVID-19 Drug Trial Aerpio Pharmaceuticals Inc (NASDAQ: ARPO) and Quantum Leap Healthcare announced an agreement to evaluate razuprotafib in a new randomized, investigational treatment arm in the I-SPY COVID Trial for the treatment of ARDS in adult patients with moderate-to-severe COVID-19.The stock jumped 38.11% to $1.08 in after-hours trading.I-Mab's Severe COVID-19 Treatment Candidate Found Safe, Well-Tolerated In Phase 1b/2 Study I-Mab ADR (NASDAQ: IMAB) announced interim results from a clinical study of TJM2 in patients with cytokine release syndrome associated with severe COVID-19, with the Part 1 portion of the study evaluating the safety and tolerability of TJM2 in a total of 24 patients who were randomized at a ratio of 1:1:1 to receive either a single dose of 3 mg/kg TJM2, a single dose of 6 mg/kg TJM2 or placebo, administered by intravenous infusion.The company noted that a Data Monitoring Committee that evaluated data from Part 1 of the study concluded that it can commence the Part 2 of the study as planned, indicating TJM2 is safe and well-tolerated in the severe COVID-19 patients.The stock added 3.01% to $24.98 in after-hours trading.New Immunomedics CEO Quits Due To Coronavirus-Related Logistics Issues Immunomedics, Inc. (NASDAQ: IMMU) said CEO Harout Semerjian has decided to step down from his role effective immediately. Semeriian assumed the CEO role April 16 after his predecessor quit in the wake of a CRL for the company's lead antibody-drug conjugate sacituzumab govitecan and accusations regarding a data integrity breach.View more earnings on IBBThe company said the move was precipitated by the unfortunate significant logistical obstacles presented by the COVID-19 pandemic, including Semerjian's ability to fully assume his duties as CEO.Dr. Behzad Aghazadeh, executive chairman of Immunomedics, will continue to support the in an executive leadership role going forward, the company said.The stock was down 1.96% to $33.50 in the premarket session. FDA Grants Moleculin's Pre-IND Meeting Request For Coronavirus Drug Candidate, Shares to Resume TradingMoleculin Biotech, Inc., (NASDAQ: MBRX) said the FDA has granted the company's request for a pre-IND meeting to provide guidance regarding its plan to study its drug candidate WP1122 in a clinical trial for patients with COVID-19.The company said it plans to submit its IND application in the second half of the year, contingent on the guidance received from its pre-IND meeting with the FDA.Moleculin said in a separate release that Nasdaq has said its shares, which have been halted since May 4 due to questions regarding accuracy of information in the marketplace about its drug candidate for coronavirus, will begin trading again Thursday.Offerings Iovance Biotherapeutics Inc (NASDAQ: IOVA) said it intends to offer $500 million of its common stock, subject to market and other conditions, in an underwritten public offering. All of the shares in the offering are to be sold by the company.The stock was down 12.05% to $33.50 in Thursday's premarket session.BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) priced its underwritten public offering of 18.71 million shares at $4.50 per share. The company also said it is offering to certain investors pre-funded warrants to purchase up to an aggregate of 3.51 million shares of its common stock at $4.49 per pre-funded warrant.The company expects to raise gross proceeds of $100 million from the offering.The stock was down 7.25% at $4.67 premarket. Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) said it intends to offer in an underwritten public offering and subject to market and other conditions, $250 million worth of its common stock. All of the shares are being offered by the company.Arena shares were down 12.45% at $50.90 premarket. Arcus Biosciences Inc (NYSE: RCUS) said it has commenced an underwritten public offering of its common stock. All the shares in the offering will be sold by the company.The stock was down 1.29% at $26.70 premarket Thursday.On The Radar Earnings * Adverum Biotechnologies Inc (NASDAQ: ADVM) (after the close) * Geron Corporation (NASDAQ: GERN) (after the close)Related Link: Merck's Coronavirus Plan Of Attack: 2 Partnerships, M&A Deal Aimed At Treatment, Vaccine Development See more from Benzinga * The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    • I-Mab Announces Upcoming Participation at June Conferences
      PR Newswire

      I-Mab Announces Upcoming Participation at June Conferences

      I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders, today announced its participation in the following conferences in June. Details of the conferences and management presentation are as follows:

    • I-Mab Reports Interim Results from Part 1 Study for Anti-GM-CSF Antibody TJM2 to Treat COVID-19 Patients with -Cytokine Release Syndrome
      PR Newswire

      I-Mab Reports Interim Results from Part 1 Study for Anti-GM-CSF Antibody TJM2 to Treat COVID-19 Patients with -Cytokine Release Syndrome

      I-Mab (NASDAQ: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced interim results from a multi-center, double blinded, randomized, placebo-controlled, three-arm clinical study (NCT04341116) of TJM2 in patients with cytokine release syndrome (CRS) associated with severe coronavirus disease 2019 (COVID-19).

    • I-Mab and Genexine Announce China NMPA Clearance for Phase 2 Clinical Trial of TJ107/HyLeukin-7™ in Glioblastoma Multiforme
      PR Newswire

      I-Mab and Genexine Announce China NMPA Clearance for Phase 2 Clinical Trial of TJ107/HyLeukin-7™ in Glioblastoma Multiforme

      I-Mab (NASDAQ: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders, and Genexine Inc. (KOSDAQ: 095700), a clinical-stage biotechnology company focused on developing innovative immunotherapeutics and novel long-acting biologics, today announced that the China National Medical Products Administration (NMPA) has cleared the initiation of a Phase 2 clinical trial of TJ107/HyLeukin-7™ (Efineptakin alfa), the novel long-acting recombinant human interleukin-7 (rhIL-7), in lymphopenic patients with newly-diagnosed glioblastoma multiforme (GBM). In addition, the two companies expanded their collaboration beyond the initial agreement to include development of TJ107/HyLeukin-7™ for this indication.

    • I-Mab Expands Global Presence with New Hong Kong Office
      PR Newswire

      I-Mab Expands Global Presence with New Hong Kong Office

      I-Mab (NASDAQ:IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders, today announced the opening of its Hong Kong office. The newest addition expands I-Mab's existing footprint in Shanghai, Beijing and Rockville, MD. The Hong Kong office, located in Central, will serve as a regional hub for capital markets and investor relations activities for I-Mab.

    • First Patient Dosed with I-Mab's CD73 Antibody TJD5 in Phase 1/2 Clinical Trial in China for Advanced Solid Tumors
      PR Newswire

      First Patient Dosed with I-Mab's CD73 Antibody TJD5 in Phase 1/2 Clinical Trial in China for Advanced Solid Tumors

      I-Mab (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, today announced that the first patient has been dosed in a Phase 1/2 clinical study in China to evaluate I-Mab's proprietary CD73 antibody TJD5, also known as TJ004309, in patients with advanced solid tumors (CTR20200445; NCT04322006).

    • GlobeNewswire

      I-Mab Filed 2019 Annual Report on Form 20-F

      SHANGHAI, China and ROCKVILLE, MD., April 29, 2020 -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development.

    • GlobeNewswire

      I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Multiple Myeloma in Mainland China

      I-Mab (IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, and MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR), today jointly announced that the first patient has been dosed in a phase 3 clinical study in mainland China to evaluate MorphoSys’ investigational human CD38 antibody TJ202/MOR202 in combination with lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma (r/r MM). Under a licensing agreement with MorphoSys, I-Mab has exclusive rights for development and commercialization of TJ202/MOR202 in mainland China, Taiwan, Hong Kong and Macao.

    • GlobeNewswire

      I-Mab Announces Upcoming Participation at May Conferences

      SHANGHAI, China and ROCKVILLE, MD., April 24, 2020 -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development.

    • GlobeNewswire

      I-Mab Announces Upcoming Participation at April Conferences

      SHANGHAI, China, and ROCKVILLE, MD., April 06, 2020 -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development.

    • GlobeNewswire

      I-Mab Announces IND Clearance from FDA for TJM2 to Treat Cytokine Release Syndrome (CRS) Associated with Severe Coronavirus Disease 19 (COVID-19)

      I-Mab (IMAB) ( the “Company”), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug application (IND) to initiate clinical study for TJM2 to treat cytokine release syndrome (CRS) associated with severe illness caused by the coronavirus disease 2019 (COVID-19). The Company has also obtained central institutional review board (IRB) approval from the Western Institutional Review Board on the same day.

    • GlobeNewswire

      I-Mab Announces First Patient Dosed in Phase 1/2a Clinical Trial of Anti-CD47 Antibody, TJC4, in China

      - The clinical study will evaluate the safety and preliminary efficacy of TJC4, in patients with relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome.

    • GlobeNewswire

      I-Mab Announces Financial Results for the Full Year Ended December 31, 2019, and Provides Corporate Update

      Successfully completed initial public offering raising approximately $114.5 million in gross proceeds Continued execution across broad pipeline portfolio; multiple clinical.

    • ACCESSWIRE

      I-Mab - ADR to Host Earnings Call

      NEW YORK, NY / ACCESSWIRE / March 31, 2020 / I-Mab - ADR (NASDAQ:IMAB) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 31, 2020 at 8:00 AM Eastern ...

    • GlobeNewswire

      I-Mab Submits IND Application to Initiate Study of TJM2 for Treatment of Cytokine Storm Associated with Severe COVID-19 in South Korea

      -The clinical study will explore the potential of TJM2, an anti-GM-CSF monoclonal antibody, to treat cytokine release syndrome in severe and critically ill patients with.

    • GlobeNewswire

      I-Mab Enters into Strategic Regional Partnership with Kalbe Genexine Biologics for Commercialization Rights of CD73 Antibody, TJD5, for Immuno-Oncology

      - Kalbe Genexine Biologics (“KG Bio”) will receive right of first negotiation for an exclusive license to potentially commercialize I-Mab’s TJD5, in Southeast Asia and other.

    • GlobeNewswire

      I-Mab Expands Global Out-Licensing and Business Development Efforts

      I-Mab (the “Company”) (IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, today announced the appointment of Fernando J. Sallés, Ph.D., CLP®, as Senior Vice President, Head of U.S. & EU Business Development, effective March 30, 2020. In this newly created role, Dr. Sallés will initially be responsible for leading global out-licensing efforts and concluding global co-development partnerships/strategic alliances with large pharma and biotech companies in the United States and EU, helping to expedite the development and market entry of the Company’s products.

    • GlobeNewswire

      I-Mab Appoints Gigi Feng as Vice President and Global Head of Corporate Communications

      I-Mab (the “Company”) (IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, today announced the appointment of Gigi Feng as Vice President, Global Head of Corporate Communications, effective April 20th, 2020. Reporting to I-Mab’s Board of Directors, Feng will oversee all communications across I-Mab, partnering with the executive team to communicate the Company’s strategic narrative, R&D innovation, external collaborations and more.

    • GlobeNewswire

      I-Mab Biopharma Announces Development of TJM2 to Treat Cytokine Release Syndrome Associated with Severe and Critically-Ill Patients with Coronavirus Disease (COVID-19)

      -The clinical study will explore the potential of TJM2, a proprietary mAb against GM-CSF, to fight "cytokine storm” during severe COVID-19 disease -The study to be conducted.

    • GlobeNewswire

      I-Mab to Report Financial Results for Full Year 2019 and Provide Corporate Update on March 31, 2020

      SHANGHAI, China and ROCKVILLE, MD., March 11, 2020 -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development.

    • GlobeNewswire

      I-Mab Announces Upcoming Participation at March Conferences

      SHANGHAI, China and ROCKVILLE, MD., Feb. 25, 2020 -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development.

    • GlobeNewswire

      I-Mab Announces Partial Exercise of Over-Allotment Option in Initial Public Offering

      SHANGHAI, China and ROCKVILLE, MD., Feb. 10, 2020 -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development.

    • GlobeNewswire

      I-MAB Announces Pricing of U.S. Initial Public Offering

      SHANGHAI, China and ROCKVILLE, Md., Jan. 17, 2020 -- I-Mab (“I-Mab” or the “Company”) (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery,.